None listed
Conditions
Interventions
Dietary Supplement : It is randomly assigned to one of the two groups and oral intake of human-applied test products once a day for 8 weeks.
- HK L-137 group: 1 capsule once a day, 1 capsule at a time
Sponsors
Chong Kun Dang Bio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Those who voluntarily decide to participate in this clinical study and signs the informed consent 2) Men and women aged 19 to 75 years inclusive at the time of signing the informed consent 3) Those who have at least respiratory infection symptoms twice for more than 12 months prior to screening
Exclusion criteria
Exclusion criteria: 1) Those who are pregnant or lactating women 2) Those who have a history of alcohol abuse or are chronically consuming alcohol 3) Those who have a serious accompanying disease inappropriate for participation in the study 4) Those who have a history of psychiatric diseases or have a disease that interferes with participation in the study 5) Those who have a disease that can affect the immune response, such as asthma 6) Those who have a clinically significant liver disorder or kidney disorder 7) Those who regularly ingested probiotics (lactic acid bacteria, etc.) and prebiotics (e.g., dietary fiber, fructo oligosaccharide, etc.) for one month before screening 8) Those who continuously takes medicines, etc. that may affect the immune response within one month prior to screening 9) Those who have a significant infection that is active within three months prior to screening 10) Those who are required to take drugs continuously that are deemed to affect the results of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nature Killer cell activity | — |
Secondary
| Measure | Time frame |
|---|---|
| Monocyte;PSS(Perceived Stress Scale);WURSS-21: Wisconsin Upper Respiratory Symptom Survey-21 | — |
Countries
Korea, Republic of
Contacts
Public ContactEunji Lee
Jeonbuk National University Hospital
Outcome results
None listed